{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T14:07:29Z","timestamp":1761919649109},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2012,10,1]],"date-time":"2012-10-01T00:00:00Z","timestamp":1349049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2012,10]]},"DOI":"10.1007\/bf03261920","type":"journal-article","created":{"date-parts":[[2013,1,4]],"date-time":"2013-01-04T01:16:56Z","timestamp":1357262216000},"page":"665-672","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Safety of Telaprevir for Chronic Hepatitis C Virus Infection"],"prefix":"10.1007","volume":"32","author":[{"given":"Huimin","family":"Qin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongtao","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaolin","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanbing","family":"Shen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongku","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Feng","family":"Ye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yingchun","family":"Xie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,13]]},"reference":[{"issue":"17","key":"1920_CR1","doi-asserted-by":"publisher","first-page":"17508","DOI":"10.1074\/jbc.M313020200","volume":"279","author":"C. Lin","year":"2004","unstructured":"Lin C, Lin K, Luong YP, et al. In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. J Biol Chem. 2004 Apr 23; 279(17): 17508\u201314","journal-title":"J Biol Chem"},{"issue":"5","key":"1920_CR2","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1345\/aph.1P430","volume":"45","author":"L.S. Smith","year":"2011","unstructured":"Smith LS, Nelson M, Naik S, et al. Telaprevir: an NS3\/4A protease inhibitor for the treatment of chronic hepatitis C. Ann Pharmacother. 2011 May; 45(5): 639\u201348","journal-title":"Ann Pharmacother."},{"issue":"5","key":"1920_CR3","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/nrgastro.2011.49","volume":"8","author":"W.P. Hofmann","year":"2011","unstructured":"Hofmann WP, Zeuzem S. A new standard of care for the treatment of chronic HCV infection. Nat Rev Gastroenterol Hepatol 2011 May; 8(5): 257\u201364","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"3","key":"1920_CR4","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1053\/j.gastro.2011.01.028","volume":"140","author":"J.M. Pawlotsky","year":"2011","unstructured":"Pawlotsky JM. The results of Phase III clinical trials with telaprevir and boceprevir presented at the Liver Meeting 2010: a new standard of care for hepatitis C virus genotype 1 infection, but with issues still pending. Gastroenterology 2011 Mar; 140(3): 746\u201354","journal-title":"Gastroenterology"},{"issue":"2","key":"1920_CR5","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1586\/eri.10.153","volume":"9","author":"T. Burney","year":"2011","unstructured":"Burney T, Dusheiko G. Overview of the PROVE studies evaluating the use of telaprevir in chronic hepatitis C genotype 1 patients. Expert Rev Anti Infect Ther 2011 Feb; 9(2): 151\u201360","journal-title":"Expert Rev Anti Infect Ther"},{"issue":"18","key":"1920_CR6","doi-asserted-by":"publisher","first-page":"1827","DOI":"10.1056\/NEJMoa0806104","volume":"360","author":"J.G. McHutchison","year":"2009","unstructured":"McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med 2009 Apr 30; 360(18): 1827\u201338","journal-title":"N Engl J Med"},{"issue":"25","key":"1920_CR7","doi-asserted-by":"publisher","first-page":"2405","DOI":"10.1056\/NEJMoa1012912","volume":"364","author":"I.M. Jacobson","year":"2011","unstructured":"Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 2011 Jun 23; 364(25): 2405\u201316","journal-title":"N Engl J Med"},{"issue":"18","key":"1920_CR8","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1056\/NEJMoa0807650","volume":"360","author":"C. Hezode","year":"2009","unstructured":"Hezode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009 Apr 30; 360(18): 1839\u201350","journal-title":"N Engl J Med"},{"key":"1920_CR9","volume-title":"Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nded)","author":"D.B. Petitti","year":"2000","unstructured":"Petitti DB. Meta-analysis, decision analysis, and cost effectiveness analysis: methods for quantitative synthesis in medicine(2nded). New York, NY: Oxford University Press; 2000"},{"issue":"25","key":"1920_CR10","doi-asserted-by":"publisher","first-page":"2417","DOI":"10.1056\/NEJMoa1013086","volume":"364","author":"S. Zeuzem","year":"2011","unstructured":"Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med. 2011 Jun 23; 364(25): 2417\u201328","journal-title":"N Engl J Med"},{"issue":"11","key":"1920_CR11","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1056\/NEJMoa1014463","volume":"365","author":"K.E. Sherman","year":"2011","unstructured":"Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011 Sep 15; 365(11): 1014\u201324","journal-title":"N Engl J Med"},{"issue":"14","key":"1920_CR12","doi-asserted-by":"publisher","first-page":"1292","DOI":"10.1056\/NEJMoa0908014","volume":"362","author":"J.G. McHutchison","year":"2010","unstructured":"McHutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010 Apr 8; 362(14): 1292\u2013303","journal-title":"N Engl J Med"},{"issue":"1","key":"1920_CR13","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(95)00134-4","volume":"17","author":"A.R. Jadad","year":"1996","unstructured":"Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996 Feb; 17(1): 1\u201312","journal-title":"Control Clin Trials"},{"issue":"4","key":"1920_CR14","first-page":"719","volume":"22","author":"N. Mantel","year":"1959","unstructured":"Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959 Apr; 22(4): 719\u201348","journal-title":"J Natl Cancer Inst"},{"issue":"3","key":"1920_CR15","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","volume":"7","author":"R. DerSimonian","year":"1986","unstructured":"DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986 Sep; 7(3): 177\u201388","journal-title":"Control Clin Trials"},{"issue":"7414","key":"1920_CR16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","volume":"327","author":"J.P. Higgins","year":"2003","unstructured":"Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003 Sep 6; 327(7414): 557\u201360","journal-title":"BMJ"},{"issue":"1","key":"1920_CR17","doi-asserted-by":"publisher","first-page":"101","DOI":"10.2307\/3001666","volume":"10","author":"W.G. Cochran","year":"1954","unstructured":"Cochran WG. The combination of estimates from different experiments. Biometrics 1954; 10(1): 101\u201329","journal-title":"Biometrics"},{"key":"1920_CR18","first-page":"15","volume":"8","author":"A. Tobias","year":"1999","unstructured":"Tobias A. Assessing the influence of a single study in the meta-analysis estimate. Stata Tech Bull 1999; 8: 15\u20137","journal-title":"Stata Tech Bull"},{"issue":"1","key":"1920_CR19","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.jhep.2011.07.016","volume":"56","author":"H. Kumada","year":"2012","unstructured":"Kumada H, Toyota J, Okanoue T, et al. Telaprevir with peginterferon and ribavirin for treatment-naive patients chronically infected with HCV of genotype 1 in Japan. J Hepatol 2012 Jan; 56(1): 78\u201384","journal-title":"J Hepatol"},{"issue":"2","key":"1920_CR20","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1053\/j.gastro.2010.10.046","volume":"140","author":"P. Marcellin","year":"2011","unstructured":"Marcellin P, Forns X, Goeser T, et al. Telaprevir is effective given every 8 or 12 hours with ribavirin and peginterferon alfa-2a or -2b to patients with chronic hepatitis C. Gastroenterology 2011 Feb; 140(2): 459\u20138 e1; quiz e14","journal-title":"Gastroenterology"},{"issue":"3","key":"1920_CR21","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1053\/j.gastro.2011.05.046","volume":"141","author":"G.R. Foster","year":"2011","unstructured":"Foster GR, Hezode C, Bronowicki JP, et al. Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections. Gastroenterology 2011 Sep; 141(3): 881\u20139 e1","journal-title":"Gastroenterology"},{"issue":"1","key":"1920_CR22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1056\/NEJM200107053450107","volume":"345","author":"G.M. Lauer","year":"2001","unstructured":"Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med 2001 Jul 5; 345(1): 41\u201352","journal-title":"N Engl J Med"},{"issue":"3","key":"1920_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.cld.2008.03.007","volume":"12","author":"W. Blonski","year":"2008","unstructured":"Blonski W, Reddy KR. Hepatitis C virus infection and hepato-cellular carcinoma. Clin Liver Dis 2008 Aug; 12(3): 661\u201374, x","journal-title":"Clin Liver Dis"},{"issue":"6","key":"1920_CR24","doi-asserted-by":"publisher","first-page":"1457","DOI":"10.1016\/j.jhep.2011.07.020","volume":"55","author":"T. Asselah","year":"2011","unstructured":"Asselah T. Realize the advance in HCV treatment, but remain cautious. J Hepatol 2011 Dec; 55(6): 1457\u201360","journal-title":"J Hepatol"},{"issue":"2","key":"1920_CR25","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.jhep.2011.08.006","volume":"56","author":"P. Cacoub","year":"2012","unstructured":"Cacoub P, Bourliere M, Lubbe J, et al. Dermatological side effects of hepatitis C and its treatment: patient management in the era of direct-acting antivirals. J Hepatol 2012 Feb; 56(2): 455\u201363","journal-title":"J Hepatol"},{"issue":"4","key":"1920_CR26","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1016\/j.jclinepi.2010.04.026","volume":"64","author":"G. Guyatt","year":"2011","unstructured":"Guyatt G, Oxman AD, Akl EA, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol 2011 Apr; 64(4): 383\u201394","journal-title":"J Clin Epidemiol"},{"issue":"7650","key":"1920_CR27","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","volume":"336","author":"G.H. Guyatt","year":"2008","unstructured":"Guyatt GH, Oxman AD, Vist GE, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ 2008 Apr 26; 336(7650): 924\u20136","journal-title":"BMJ"},{"issue":"6","key":"1920_CR28","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1111\/j.1365-2036.2012.04992.x","volume":"35","author":"P. Ramachandran","year":"2012","unstructured":"Ramachandran P, Fraser A, Agarwal K, et al. UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients. Aliment Pharmacol Ther 2012 Mar; 35(6): 647\u201362","journal-title":"Aliment Pharmacol Ther"},{"issue":"3","key":"1920_CR29","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1016\/j.cld.2011.05.013","volume":"15","author":"A. Liapakis","year":"2011","unstructured":"Liapakis A, Jacobson I. Telaprevir user\u2019s guide. Clin Liver Dis 2011 Aug; 15(3): 555\u201371","journal-title":"Clin Liver Dis"},{"issue":"3","key":"1920_CR30","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1517\/14656566.2012.653341","volume":"13","author":"V. Soriano","year":"2012","unstructured":"Soriano V, Vispo E, Poveda E, et al. Treatment failure with new hepatitis C drugs. Expert Opin Pharmacother 2012 Feb; 13(3): 313\u201323","journal-title":"Expert Opin Pharmacother"},{"issue":"Suppl. 1","key":"1920_CR31","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/j.1478-3231.2011.02709.x","volume":"32","author":"P.Y. Kwo","year":"2012","unstructured":"Kwo PY. Phase III results in Genotype 1 naive patients: predictors of response with boceprevir and telaprevir combined with pegylated interferon and ribavirin. Liver Int 2012 Feb; 32 Suppl. 1: 39\u201343","journal-title":"Liver Int"},{"issue":"9","key":"1920_CR32","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1007\/s00535-010-0287-4","volume":"45","author":"G. Ahlenstiel","year":"2010","unstructured":"Ahlenstiel G, Booth DR, George J. IL28B in hepatitis C virus infection: translating pharmacogenomics into clinical practice. J Gastroenterol 2010 Sep; 45(9): 903\u201310","journal-title":"J Gastroenterol"},{"issue":"2","key":"1920_CR33","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hep.23690","volume":"52","author":"N. Akuta","year":"2010","unstructured":"Akuta N, Suzuki F, Hirakawa M, et al. Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin. Hepatology 2010 Aug; 52(2): 421\u20139","journal-title":"Hepatology"},{"issue":"7","key":"1920_CR34","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1001\/jama.297.7.724","volume":"297","author":"J.D. Scott","year":"2007","unstructured":"Scott JD, Gretch DR. Molecular diagnostics of hepatitis C virus infection: a systematic review. JAMA 2007 Feb 21; 297(7): 724\u201332","journal-title":"JAMA"},{"issue":"4","key":"1920_CR35","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1002\/hep.24172","volume":"53","author":"I. Imhof","year":"2011","unstructured":"Imhof I, Simmonds P. Genotype differences in susceptibility and resistance development of hepatitis C virus to protease inhibitors telaprevir (VX-950) and danoprevir (ITMN-191). Hepatology 2011 Apr; 53(4): 1090\u20139","journal-title":"Hepatology"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261920.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/BF03261920\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261920","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/BF03261920.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,28]],"date-time":"2022-07-28T23:08:57Z","timestamp":1659049737000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/BF03261920"}},"subtitle":["A Meta-Analysis of Randomized Controlled Trials"],"short-title":[],"issued":{"date-parts":[[2012,10]]},"references-count":35,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1007\/bf03261920","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,10]]},"assertion":[{"value":"13 December 2012","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}